The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK inhibitor combinations, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’s Tafinlar + Mekinist, and Pfizer / Array BioPharma’s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.
Geographies: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands / generics and epidemiological subpopulations.
Emerging therapies: Phase III: 10 drugs; Phase II: 7 drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.